Diabetes Devices And Drugs Market Analysis & Forecast: 2025-2032

Diabetes Devices and Drugs Market Size and Forecast – 2025 to 2032

Diabetes Devices And Drugs Market is estimated to be valued at USD 191.66 Bn in 2025 and is expected to reach USD 373.49 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 10.0% from 2025 to 2032.

Key Takeaways

• By Category, Diagnosis and Monitoring hold the largest market share in 2025 on account of the increasing prevalence of diabetes.
• By Disease Type, Type 2 diabetes acquires the prominent share in 2025 owing to the growing Advancements in Diabetes Drugs and Insulin Therapies.
• By Region, North America dominates the overall market with an estimated share of 38.7% in 2025 as advanced healthcare infrastructure and access to care across the United States.

Market Overview

The Diabetes Devices and Drugs Market is expanding quickly within the global healthcare sector, fueled by the rising prevalence of diabetes and the growing need for more effective and innovative treatment options. Diabetes, a chronic condition that impacts the body's ability to regulate blood sugar, is divided into Type 1 and Type 2 diabetes, with Type 2 accounting for the majority of cases worldwide.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Role of AI (Artificial Intelligence) in the Diabetes Devices and Drugs Market

AI-powered devices like continuous glucose monitors (CGMs) and smart insulin pumps collect vast amounts of real-time data. AI algorithms analyze this data to provide personalized insights, predict blood sugar trends, and recommend timely adjustments, helping patients manage their condition more effectively.

In June 2025, IBM and Roche developed AI-powered solution designed to simplify daily diabetes management: Roche’s Accu-Chek® SmartGuide Predict app. This launch highlights the power of cross-industry collaboration and teamwork in enhancing support for people with diabetes and advancing healthcare delivery.

Reimbursement Policies in the Diabetes Devices and Drugs Market

Home blood glucose monitors (BGMs) and continuous glucose monitors (CGMs) are reimbursable under the Durable Medical Equipment (DME) benefit as defined by the Social Security Act (§1861(s)(6)). For beneficiaries to qualify for reimbursement, their DME must meet the reasonable and necessary (R&N) criteria specified in the relevant Local Coverage Determination (LCD). Additionally, specific statutory payment policy requirements must be satisfied.

Medicare expanded coverage to include therapeutic (non-adjunctive) CGM devices under the DME benefit. These devices were officially classified as therapeutic CGMs under CMS Ruling 1682R, distinguishing them from adjunctive models.

In Canada, progress toward universal pharmacare continues. In February 2024, the Minister of Health introduced Bill C-64, An Act respecting pharmacare, marking a key step in the government’s plan to implement national, single-payer coverage for a broad range of diabetes medications. This initiative will be developed in partnership with willing provinces and territories (PTs), aiming to improve access and affordability for diabetes treatments across the country.

End-user Feedback and Unmet Needs in the Diabetes Devices and Drugs Market End-user Feedback and Unmet Need s

• Preference for Simplicity and User-Friendliness: Many patients prefer diabetes management devices that are easy to use and require minimal technical knowledge. Continuous glucose monitors (CGMs) and insulin pumps need to be intuitive, offering seamless integration with smartphones or other wearable technologies for convenience.
• Desire for Cost-Effective Solutions: A significant portion of end-users, particularly in developing regions, seek affordable devices and medications. High costs of advanced technologies, like CGMs and insulin pumps, remain a major concern for many, hindering broader adoption.
• Real-Time Data and Predictive Features: Users increasingly demand devices that offer real-time glucose monitoring and predictive analytics to manage fluctuations more effectively. AI-powered solutions that offer personalized insights into glucose trends and recommend actions are in high demand.

Segmental Insights

To learn more about this report, Download Free Sample

Diabetes Devices and Drugs Market Insights, by Category -  Diagnosis and Monitoring contribute the highest share of the market owing to its Growing Focus on Early Diagnosis and Preventive Healthcare

The increasing demand for accurate, real-time management of blood glucose levels drives the need for Diagnosis and Monitoring in the Diabetes Devices and Drugs Market. As diabetes, especially Type 2 diabetes, becomes more prevalent, the need for advanced diagnostic tools like continuous glucose monitors (CGMs) and blood glucose meters grows. These devices track glucose fluctuations, allowing patients and healthcare providers to adjust treatment plans promptly. The rising focus on early diagnosis and preventive care, coupled with technological advancements in monitoring systems, further boosts market demand. In May 2023, Roche Diabetes Care India (RDC India) began manufacturing the "Accu-Chek Active" blood glucose monitoring device in India. Sanmina-SCI India produces the product at its Chennai facility, and Parekh Integrated Services distributes it.

Diabetes Devices and Drugs Market Insights, by Disease Type -  Type 2 Diabetes contribute the highest share of the market

The rising prevalence of Type 2 diabetes drives significant demand for treatment and monitoring solutions in the Diabetes Devices and Drugs Market. Factors like rising obesity rates, sedentary lifestyles, and unhealthy diets contribute to the growing incidence of Type 2 diabetes, especially in developed countries. This increase in cases creates a need for more advanced diagnostic tools, medications, and management devices, such as insulin pumps, oral drugs, and continuous glucose monitors (CGMs). As awareness grows and early detection gains more focus, the market is set to expand rapidly.

For instance, in March 2025, Sun Pharmaceutical, planned to launch its experimental anti-obesity and type 2 diabetes drug within the next four to five years, according to Managing Director Dilip Shanghvi's statement on Friday.

Regional Insights

To learn more about this report, Download Free Sample

North America Diabetes Devices and Drugs Market Trends

North America dominates the overall market with an estimated share of 38.7%, its growing rapidly due to the rising prevalence of Type 2 diabetes, increasing awareness, and technological advancements. The demand for continuous glucose monitors (CGMs), insulin pumps, and smart insulin pens is rising, while innovations in diabetes medications like SGLT-2 inhibitors and GLP-1 receptor agonists are gaining popularity. The U.S. dominates the market, benefiting from a robust healthcare infrastructure, government support, and favorable reimbursement policies, which continue to drive the region’s market share and expansion. Apart from this, the growing technological innovations is also acting as one of the major factors adding to the diabetes devices and drugs market share. In November 2024, Sol-Millennium® Medical Group launched the InsuJet™ Needle-free Device, a new insulin delivery system for diabetic patients. This innovative technology aims to improve patients’ quality of life by eliminating the pain of traditional needle injections.

Asia Pacific Diabetes Devices and Drugs Market Trends

The Asia-Pacific Diabetes Devices and Drugs Market is growing rapidly due to the rising incidence of diabetes, particularly in countries like China and India. Urbanization, lifestyle changes, and an aging population are driving the increased demand for diabetes management solutions, including continuous glucose monitors (CGMs), and oral medications. The region's market share is expanding, with Japan and South Korea leading the way in adopting advanced technologies. For instance, in February 2024, Eli Lilly introduced Mounjaro, its diabetes drug and widely popular obesity treatment, in India.

United States Diabetes Devices and Drugs Market Trends

The United States Diabetes Devices and Drugs Market continues to lead globally, driven by the high prevalence of Type 2 diabetes, technological innovations, and strong healthcare infrastructure. In addition, the market is seeing increased adoption of new drug classes like GLP-1 receptor agonists and SGLT-2 inhibitors. The U.S. holds the largest market share, benefiting from favorable reimbursement policies, government healthcare programs, and widespread awareness about diabetes management, making it a key driver of global market trends.

For Instance, in April 2025, Meitheal Pharmaceuticals, Inc., a fully integrated biopharmaceutical company based in Chicago, announced today that it has received U.S. Food and Drug Administration (FDA) approval and launched its liraglutide injection (18mg/3mL), the generic equivalent of Victoza®2, in the U.S.

India Diabetes Devices and Drugs Market Trends

The rising prevalence of Type 2 diabetes in India, driven by changing lifestyles, urbanization, and an aging population, is fueling growth in the diabetes devices and drugs market. India’s rapid economic development, improving healthcare system, and increasing availability of affordable medications and devices are driving the market forward. While the country’s market share remains smaller compared to Western nations, government initiatives and a growing health-conscious population are expected to further accelerate market expansion in the coming years.

For instance, in March 2025, Morepen Laboratories Ltd. introduced a new medication for chronic kidney disease, heart failure, and Type 2 diabetes. The company stated that Empamore offers millions of patients in India a high-quality, affordable alternative to existing treatments.

Market Report Scope

Diabetes Devices and Drugs Market Report Coverage

Diabetes Devices and Drugs Market Trend

Increasing government initiatives to promote research and development in the field of diabetes management

Government initiatives have been fuelling the research and development in the field of diabetes management significantly. This is expected to drive the diabetes devices and drugs market growth over the forecast period. For instance, in March 2021, the Government of Canada announced a new partnership with the Netherlands to fund type 2 diabetes research. This initiative commemorated the 100th anniversary of the discovery of insulin and invests in new research that will support the development of new preventive and therapeutic approaches to reverse the upward trajectory of diabetes prevalence and associated morbidities and reduce the impact of diabetes on individuals, families, and communities. This is further accelerating the diabetes devices and drugs market share.

Diabetes Devices and Drugs Market Opportunity

Personalized Medicine and Drug Innovation

An important opportunity in the market is the development of personalized treatment plans and innovative diabetes medications. Advances in genomics and patient-specific data are driving the shift towards more tailored drug therapies. GLP-1 receptor agonists and SGLT-2 inhibitors are gaining popularity as they effectively control glucose levels while addressing common comorbidities in diabetic patients, such as cardiovascular diseases and weight management. These drugs are increasingly seen as beneficial for providing more comprehensive care, improving patient outcomes, and reducing complications associated with diabetes.

Diabetes Devices and Drugs Market News

• In April 2025, the FDA approved the Dexcom G7 continuous glucose monitor with a 15-day sensor wear time for adults 18 and older with type 1 or type 2 diabetes.
• In March 2025, Tandem Diabetes Care, Inc. launched Control-IQ+ technology, an advanced hybrid closed-loop algorithm. Compatible with the t:slim X2 insulin pump and Tandem Mobi System, Control-IQ+ is now available for people with type 1 diabetes aged 2 and older, as well as adults with type 2 diabetes.
• In February 2025, Senseonics Holdings, Inc. (NYSE American: SENS) announced it filed for CE Mark registration of the Eversense® 365 implantable continuous glucose monitoring system.
• In February 2025, Owens & Minor launched the ByramConnect digital health platform for diabetes and other chronic conditions. The platform integrates the Welldoc App, giving care teams a comprehensive view of patient health by combining data from fitness trackers, glucose monitors, blood pressure devices, and medical labs.

Analyst Opinion (Expert Opinion)

• The Diabetes Devices and Drugs Market is undergoing a significant transformation, driven by innovation, patient-centered approaches, and regulatory influences. From my perspective, the most promising advancements lie in personalized diabetes care, which is fueled by emerging technologies and new treatment methods. The growing emphasis on precision medicine and the increasing availability of genetic testing are enabling more customized drug regimens. In my view, this shift towards tailored treatments will define the future of diabetes management.
• The rising use of GLP-1 receptor agonists highlights the move toward drugs that not only manage blood glucose but also address key comorbidities like cardiovascular disease and obesity, both of which are becoming more prevalent among diabetic patients. A prime example of this is the success of semaglutide (Ozempic), which has shown impressive results in weight loss and reducing heart disease risk. As patient outcomes continue to improve with such therapies, I believe they will eventually replace older insulin-based regimens, offering more comprehensive care.
• In terms of diabetes devices, the rapid growth of continuous glucose monitors (CGMs) is noteworthy. Devices like the Dexcom G6 and Freestyle Libre are revolutionizing glucose monitoring by not only providing real-time data but also integrating with smartphone apps and AI analytics to deliver predictive insights. This shift from reactive to proactive care is a game-changer. By leveraging data from these devices, healthcare providers will be able to make more informed decisions in real-time, optimizing insulin delivery and reducing the risks of hypoglycemia.

Market Segmentation

• Global Diabetes Devices and Drugs Market, By Category
  • Diagnosis and Monitoring
    • Blood Glucose Monitoring Devices
    • Software Programs for Diabetes Monitoring
    • Artificial Pancreas
    • Other Testing Devices
  • Therapeutics
    • Insulin
    • Insulin Delivery
    • Oral Hypoglycemic Agents
    • Cell Therapies
• Global Diabetes Devices and Drugs Market, By Disease Type
  • Type 2 Diabetes
  • Type 1 Diabetes
• Global Diabetes Devices and Drugs Market, By Region
  • North America
    
    • U.S.
    • Canada
  • Latin America
    
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    
    • South Africa
    • Central Africa
    • North Africa
• Company Profiles
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • DexCom
  • Eli Lilly and Company
  • Companion Medical
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals
  • Johnson & Johnson
  • Lupin Ltd.
  • Hoffmann-La Roche AG
  • DreaMed Diabetes
  • Hua Medicine
  • Sanofi

Sources

Primary Research Interviews

• Interviews with healthcare professionals, including endocrinologists, diabetologists, and primary care physicians.
• Discussions with diabetes patients and caregivers to understand user experiences with devices and drug therapies.
• Conversations with executives and R&D leaders from pharmaceutical and medical device companies.
• Interviews with regulatory authorities and policymakers involved in diabetes care and treatment.

Databases

• PubMed for peer-reviewed research articles on diabetes treatments and device innovations.
• ClinicalTrials.gov for information on ongoing and completed clinical trials related to diabetes drugs and devices.
• FDA and EMA databases for drug approvals, device clearances, and regulatory guidelines.
• DrugBank for detailed drug information, including those related to diabetes management.

Magazines

• Diabetes Care: Official journal of the American Diabetes Association, offering insights into the latest research and innovations in diabetes care.
• Diabetic Living: A lifestyle magazine that offers updates on diabetes management products, treatments, and patient stories.
• Endocrine Today: Provides news, research updates, and clinical insights on diabetes and endocrinology-related topics.

Journals

• The Lancet Diabetes & Endocrinology: A leading journal that publishes research on new drug therapies, clinical trials, and device innovations in diabetes.
• Diabetes Technology & Therapeutics: A journal focused on the development and application of diabetes technologies, including devices and software solutions.
• The Journal of Diabetes Science and Technology: Provides research and reviews on the latest advancements in diabetes monitoring and treatment technologies.

Newspapers

• The New York Times: Regularly covers health trends, including diabetes research, treatments, and policy changes.
• The Guardian: Reports on healthcare innovations, including diabetes drug development and device technologies.
• The Wall Street Journal: Features articles on medical advancements, regulatory updates, and market developments related to diabetes treatments and technologies.

Associations

• American Diabetes Association (ADA): Provides a wealth of resources on diabetes management, treatments, and ongoing research.
• International Diabetes Federation (IDF): Offers global statistics, policy advocacy, and research updates on diabetes prevalence and management.
• European Association for the Study of Diabetes (EASD): Provides expert insights, conferences, and publications on diabetes research and care.
• Diabetes UK: A charity providing valuable research, policy, and patient care data related to diabetes in the UK.

Public Domain Sources

• World Health Organization (WHO): Offers global data, reports, and guidelines on diabetes prevalence, management, and treatment strategies.
• Centers for Disease Control and Prevention (CDC): Provides extensive information on diabetes statistics, trends, and public health initiatives.
• National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Offers research and statistical data on diabetes prevention, treatment, and complications.
• U.S. Food and Drug Administration (FDA): Publishes approved drug lists, device clearances, and regulatory guidelines for diabetes treatments and devices.

Proprietary Elements

• CMI Data Analytics Tool, and Proprietary CMI Existing Repository of information for last 8 years